Vitamin K1 (Synonyms:叶绿醌; Phylloquinone; Phytomenadione)
目录号 : KM18748 CAS No. : 84-80-0 纯度 : ≥98%

Vitamin K1是一种天然存在的维生素。是血液凝固,骨和血管代谢所必须的。

规格 价格 是否有货 数量
500mg
In-stock
1g
In-stock
5g
In-stock
10g 询价 In-stock
50g 询价 In-stock

Other Forms of Rapamycin:

KKL Med 的所有产品和服务仅用于科学研究,不能被用于人体,兽医,我们也不向个人提供产品和服务。
生物活性

Vitamin K1 a naturally occurring vitamin required for blood coagulation and bone and vascular metabolism.

体外研究

Phylloquinone (Vitamin K1) is a prenylated naphthoquinone that is synthesized exclusively by plants, green algae, and some species of cyanobacteria, where it serves as a vital electron carrier in photosystem I and as an electron acceptor for the formation of protein disulfide bonds. In humans and other vertebrates, phylloquinone plays the role of a vitamin (vitamin K1) that is required for blood coagulation and bone and vascular metabolism. Phylloquinone from green leafy vegetables and vegetable oil represents the major dietary source of vitamin K for humans. Vitamin K1 treatment causes a significant antiproliferative effect and induces apoptosis in Caco-2, HT-29, and SW480 cell lines, with the involvement of the MAPK pathway. A concomitant and significant decrease in the polyamine biosynthesis occurr.

体内研究

Subjects who increase their dietary intake of vitamin K during the follow-up had a 51% reduced risk of incident diabetes compared with subjects who decrease or does not change the amount of phylloquinone intake. Vitamin K supplementation reverses the high fat diet induced bone deterioration by modulating osteoblast and osteoclast activities and prevent bone loss in a high-fat diet-induced obese mice. Application of vitamin K1 to the skin has been used for suppression of pigmentation and resolution of bruising. The effects produced by the topical vitamin K1 shows significant healing when compared with control group in parameters such as wound contraction, epithelialization period, hydroxyproline content and tensile strength.

分子式
C31H46O2
分子量
450.70
CAS号
84-80-0
中文名称
维生素 K1;叶绿醌
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Pure form -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

Ethanol : ≥ 50 mg/mL (110.94 mM)

DMSO : 5.6 mg/mL (12.43 mM; Need ultrasonic and warming)

* "≥" means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.2188 mL 11.0939 mL 22.1877 mL
5 mM 0.4438 mL 2.2188 mL 4.4375 mL
10 mM 0.2219 mL 1.1094 mL 2.2188 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% EtOH    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (5.55 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.55 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 EtOH 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

  • 2.

    请依序添加每种溶剂: 10% EtOH    90% (20% SBE-β-CD in saline)

    Solubility: 2.5 mg/mL (5.55 mM); Suspended solution; Need ultrasonic

    此方案可获得 2.5 mg/mL (5.55 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 EtOH 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

  • 3.

    请依序添加每种溶剂: 10% EtOH    90% corn oil

    Solubility: ≥ 2.5 mg/mL (5.55 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.55 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 EtOH 储备液加到 900 μL玉米油中,混合均匀。

临床试验
科研文献
The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
在线客服
咨询热线
400-881-9290
关注微信公众号